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Background: An economic value calculation was performed to estimate the lifetime net present 
value of in vitro fertilization (IVF) in Ukraine, Belarus, and Kazakhstan.
Methods: Net lifetime tax revenues were used to represent governmental benefits accruing from 
a hypothetical cohort of an IVF population born in 2009 using the methodology of generational 
accounting. Governmental expenses related to this population included social benefits, education 
and health care, unemployment support, and pensions. Where available, country-specific data 
referencing official sources were applied.
Results: The average health care cost needed to achieve one additional birth from the gov-
ernmental perspective varied from $2,599 in Ukraine to $5,509 in Belarus. The net present 
value from the population born using IVF was positive in all countries: for Ukraine ($9,839), 
Belarus ($21,702), and Kazakhstan ($2,295). The break-even costs of drugs and supplies per 
IVF procedure is expected to be $3,870, $8,530, and $1,780, respectively. Probabilistic sensi-
tivity analyses based on 5,000 simulations show that the average net present value per person 
remains positive: $1,894±$7,619, $27,925±$12,407, and $17,229±$24,637 in Ukraine, Belarus, 
and Kazakhstan, respectively.
Conclusion: Financing IVF may represent a good investment in terms of governmental finan-
cial returns, even in lower-income countries with state-financed health care systems such as 
Ukraine, Belarus, and Kazakhstan.
Keywords: in vitro fertilization, economic value of life, developing countries
Introduction
Infertility is a common problem in many countries. In Central and Eastern European 
and Central Asian regions, countries report high rates of abortion, while at the same 
time displaying higher levels of secondary infertility (females with previous life births). 
Additionally, the prevalence of primary infertility (females with no previous life births) 
is significantly higher in Ukraine than in other countries of the region, reaching a level 
of $3% of the female population.1
Despite an increasing medical demand for infertility treatments, public funding 
challenges for in vitro fertilization (IVF) exist in a number of jurisdictions. While some 
countries (such as France, Spain, and Israel) provide full coverage of IVF treatments 
as a matter of policy, others either partially cover expenses (eg, Portugal, Sweden, 
 Turkey), or fail to cover it at all (eg, India, the People’s Republic of China).2 Meanwhile, 
when coverage for IVF is absent or incomplete, as is the case throughout the USA, it 
may lead to cases where IVF treatments are unaffordable to couples who need it most. 
Moreover, and of particular interest from a governmental perspective, a number of 
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economic studies have concluded that there are long-term 
financial benefits to be gained from creating new citizens who 
will eventually become future taxpayers. The cost-efficiency 
of state investments in IVF is assessed by calculation of net 
income, usually expressed through taxes and other state 
revenues received from the working  population. Economic 
evaluations revealed that there were net tax benefits of IVF 
financing in both high-income countries (eg, the USA, UK, 
Denmark, Sweden)3–7 and medium-income countries like 
Brazil.8 Net income gained from the IVF populations in all 
countries studied was positive; however, the largest gain was 
found for the UK (£109,939), while the smallest gain was 
found for Brazil (US$ 61,428).
While encouraging, these results may not be easily used 
in the decision-making process in other countries,9 such as 
those of the Central and Eastern European region. Besides 
putative differences in health care systems and popula-
tion characteristics, the country’s wealth must be taken 
into account when considering the efficiency of medical 
 technologies. For example, in lower-income countries, costly 
medical technologies potentially may be less cost-efficient 
than they would be in higher-income countries. Countries 
of the Central and Eastern European region have, on aver-
age, a much lower gross domestic product (GDP) than their 
Western European or North American counterparts; thus, the 
generalizability may be questionable for economic studies 
on IVF subsidies from high-income countries (like the USA 
and UK) to lower-income jurisdictions.
Finally, the economic impact for the population 
(expressed as the difference between state spending and 
economic benefits), may not be directly proportional to the 
GDP, depending more on internal policy of the country, 
such as tax level, social contributions, net revenues from 
public enterprises, and so on. Thus, financing of IVF also 
may be cost-efficient for governments of countries with rela-
tively low GDP per capita level. For example, while having 
universal health care coverage and free access to medical 
procedures for their respective populations, governments in 
former Soviet Union countries (such as Ukraine, Belarus, 
Kazakhstan) do not consider IVF a priority, so provide only 
limited, insufficient funds for its coverage. However, eco-
nomic analysis may be a justification for reexamining their 
policies where IVF coverage is concerned.
With the above discussion as a rationale, the present 
study was conducted to: assess the economic cost and ben-
efits of financing IVF technologies (one cycle per woman) 
in Ukraine, Belarus, and Kazakhstan from the governmental 
perspective; explore relationships between GDP per capita 
and level of financial impact on the population; and address 
transferability of the received results to other countries of 
the Central and Eastern European region.
Materials and methods
Model design
Similar to previous studies, an economic model using the 
methodology of generational accounting was developed 
to estimate for Ukraine, Belarus, and Kazakhstan whether 
publicly funded IVF treatments result in a financial benefit, 
by calculating the net revenue gained from a child conceived 
via IVF in each country.3–8 Generational accounting evaluates 
whether there will be sufficient tax revenue in the future to 
pay for current investments into IVF programs by calculat-
ing the net present value (NPV) of lifetime net taxes (gross 
taxes minus financial expenditures of the government on 
population). Because taxation remains the main source of 
revenue for most states,5 using this applied approach provides 
an appropriate assessment of rationality for IVF investments 
by the governments.
In the model we defined five stages during which popula-
tions have different expenses and revenues: prenatal; early 
childhood (from birth until school); late childhood (period 
when individual receives education including high school); 
employment; and retirement. The prenatal stage includes 
costs of IVF procedures. During the childhood stage 
the cohort is a receiver of financial flows from the state that 
consists of social support, sick leave payments, medical help, 
and education financing. During the employment period, the 
population provides revenue to the state in the form of tax 
payments, but also receives unemployment support and medi-
cal help. After retirement, the employment rate decreases, 
likewise tax contribution, but pension and health care are 
provided until the end of life. For each age category, state 
spending and income from population are calculated.
Similar to Connolly et al4–6 and Kröger and Ejzenberg,8 
the following formula was applied for assessing the NPV of 
lifetime net taxes:
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where Rt is the sum of the governmental revenues from 
individual’s age t; Et is the sum of the governmental expen-
ditures from individual’s age t; r is the discount rate; T is life 
expectancy; and K
0
 is the direct costs of IVF.
As NPV is used to estimate how much future returns 
from the investment are worth today, NPV .0 represents 
ClinicoEconomics and Outcomes Research 2015:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
349
Economic value of iVF
profitable investment, NPV =0 represents investment that is 
neither profitable nor unprofitable, and NPV ,0 represents 
unprofitable investment.7
iVF costs and outcome
Base-case scenario
Applying IVF success rates, the costs per IVF-born cohort 
and cost per live birth is calculated. Because Belarus-specific 
data for this parameter were not available, it was assumed 
in the base case that the success of IVF was equal in all 
three countries to 31.9% on average (success rate of IVF for 
35- to 37-year-old women based on the data from the Society 
for Assisted Reproductive Technology summary report on 
154,412 cycles conducted in 2011).10 The percentage of boys 
born as a result of intervention was assumed to be equal to 
the naturally born cohort and was assessed from data on sex 
ratios (51.70%, 51.5%, and 48.5% boys for born in Ukraine, 
Belarus, and Kazakhstan, respectively).11–13
Country-specific state-registered prices were used to 
assess costs of drugs and medical supplies, while the need in 
quantities of the defined medical products per one IVF cycle 
was assessed from the national state reproductive program 
in Ukraine (and considered to be similar for Belarus and 
Kazakhstan).14–16
Despite all three countries providing universal free 
health care, country-specific pregnancy-related costs are 
unknown and, for this reason, medical care expenditures 
were accounted using costs per outpatient (during IVF pro-
cedures and pregnancy) and inpatient (delivery) visits by 
WHO-CHOICE estimates.17 The average number of visits 
during one IVF cycle was calculated assuming the following 
referrals: first appointment (one visit), preparation (one visit), 
initiation (one visit), visits during treatment with fertility 
medications (five visits), egg harvesting (one visit), embryo 
transfer (one visit), consultation (one visit). Nine monthly 
visits to gynecologists and three hospitalization days were 
accounted for during pregnancy and delivery.
Although IVF procedures frequently result in multiple 
births, only one-child pregnancy was assumed in the base-
case scenario. Moreover, while during the early perinatal 
stage IVF children may require more medical assistance, in 
the life-duration model used here children conceived with 
IVF were considered to be comparable with those conceived 
naturally.
Country-specific scenario
IVF success data and rates of multiple deliveries due to IVF 
were used to understand if these country-specific  parameters 
have a significant impact on the results. The following 
assumptions were used in this scenario:
•	 The birth rate from the IVF procedure was calculated 
from data on IVF success rate and multiple pregnancies 
from the study conducted by Kupka et al18
•	 Because of the low incidence of triple births (1% for both 
Ukraine and Kazakhstan)18 this parameter was accounted 
together with dual births
•	 Because no Belarus-specific data were available, the 
rate of births due to IVF was calculated as an average in 
Russia, Belarus, and Kazakhstan18
•	 Negative health impact and higher costs associated with 
multiple pregnancies included the following: higher 
probability of dying during neonatal the period (6.4 
times);19 higher medical costs during the 1st year of life 
(the calculated cost ratio between single and dual births, 
3.29);19 and doubled payments for “maternity support” 
because of multiple births.
government transfers
In all three analyzed countries, child benefits are provided 
to the families of newborns. The first-child allowance was 
accounted in all of the cases, as it was considered that IVF is 
applied by childless families. It was also considered that one 
parent is not employed, thus receives monthly financial sup-
port for 3 years in Belarus ($82.10 per month) and Ukraine 
($16.26 per month) and for 1 year in Kazakhstan ($214.2 
per month) as ensured by state policies in these countries 
(estimation was made by the data of the Labor informa-
tional resource [http://mojazarplata.by; http://mojazarplata.
kz; mojazarplata.com.ua]). Basing estimates on data from 
accounting departments in three companies (two in Ukraine 
and one in Kazakhstan, 485 employees total), it was con-
sidered that mothers spend 15 sick leave days paid by the 
government annually per child aged 3–6 years and 10 days 
per child aged 7–12 years.
In the model, people receive health care services through-
out their lives and educational services from 0 to 19 years. 
Average expenses of governmental support for unemployed 
were calculated using official unemployment rates among 
population of working age, coverage with financial support 
for unemployed, duration of unemployment, and the amount 
of financial support.
From retirement until death, the population receives 
a pension from the government. Because data on dis-
ability prevalence were unavailable, no additional costs 
besides those associated with regular health care were 
accounted.
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state income
Government revenue accrues from income tax on population 
of working age or from the aged population who continue to 
work and pay taxes. As no age-stratified income is available 
for the study countries, average salary and tax rates were 
applied for the entire lifetime of the cohort.
Though governments receive additional revenue from 
other sources (eg, land taxes, business and enterprise pay-
ments, social contributions), income taxes are argued to be 
the largest part of state revenues; therefore, the impact of pop-
ulation increase on state income was assessed as direct taxes 
from salaries on official employment. No country-specific 
data were available bearing on a relationship between age and 
income, thus average salaries, taxes, and employment rates 
were applied to calculate the income from the working-age 
population. Moreover, a percentage of the retired population 
who are officially employed was used to calculate additional 
income from this group.
Other input parameters of the model
Life expectancy at birth for children born in 2009 was 
applied.20 All costs provided in the national currencies were 
transferred into US$ according to the national bank exchange 
rates on November 22, 2014. Rate per 1$ was equal to 15.096 
UAH (Ukraine), 10,780.00 BYR (Belarus), and 180.87 KZT 
(Kazakhstan). State expenses before birth of the IVF cohort 
were adjusted to current prices (2014) using the inflation index 
for consumer prices.21 Governmental payments and incomes 
were assumed to grow annually with the rate of annual GDP 
growth22 while being discounted at 3% in the deterministic 
model. The complete list of model input parameters together 
with a full reference list are provided in Table S1.
Validity of the model
The parameters possible for state regulation were varied 
in one-way sensitivity analysis with break-even costs cal-
culation. Subcategory analysis for women of different age 
categories presenting variations in IVF success rates was 
conducted to analyze an impact of IVF success rate on 
the results of economic analysis and, moreover, to assess 
the possible implication of limiting financing for different 
groups. As drug costs are frequently negotiable, the impact of 
changes in IVF expenses on NPV was assessed.  Additionally, 
one-way sensitivity analyses with 0%–10% discounting was 
conducted.
Probabilistic sensitivity analysis (PSA) on the most influ-
ential parameters with 5,000 simulations was conducted to 
ensure the validity of the calculation. Because the aim of PSA 
was to assess the uncertainty related to long duration of the 
model (cohort lifetime), the prenatal parameters which poten-
tially can be controlled by the government (ie, age of mother 
and IVF costs) were excluded from this assessment. Moreover, 
the IVF success rate was varied in the PSA to address the 
uncertainty of the success of the procedure. Costs included in 
the early childhood period were not varied in PSA because of 
the low impact on a lifetime model and no data on deviation 
parameters. A number of prognostic factors (such as a possible 
tax decrease in Ukraine, prolongation of the retirement age to 
the average in the Organisation for Economic Co-operation 
and Development region for all three countries) were assessed 
from publicly available information sources describing cur-
rent political trends that may affect model results. Because 
health care expenditures already are relatively low in the 
study countries, it was assumed they may only increase from 
current values or remain the same. If multiple data sources 
were available, the source providing the largest data deviation 
was used. The complete range of parameters and distributions 
used in the PSA are presented in Table S1.
Results
The observed cost variation for different schemes of IVF 
cycles applied resulted in a difference in average cost 
per cycle, with the lowest one observed in Ukraine ($732 
per cycle) and the highest one in Belarus ($1,607 per cycle). 
Using a similar IVF success rate, the average cost of one IVF 
birth from the governmental perspective varied from $2,599 
in Ukraine to $5,509 in Belarus (Table 1). 
Table 1 neonatal costs of iVF population in Ukraine, Belarus, 
and Kazakhstan (Us$)
Parameter Ukraine Belarus Kazakhstan
Drugs costs
  Option 1 iVF costs per cycle  
(47% cycles)
741 1,795 927
  Option 2 iVF costs per cycle  
(43% cycles)
538 1,129 1,243
  Option 3 iVF costs per cycle  
(10% of cycles)
782 1,902 905
  Medical supplies iVF costs  
per cycle
75 88 79
  average drugs and supplies  
costs, per one cycle
732 1,607 1,049
health care expenditures per  
one iVF cycle
48 58 147
health care pregnancy  
and delivery expenditures,  
per one birth
153 287 409
average costs needed  
to achieve one iVF birth
2,599 5,509 4,157
Abbreviation: iVF, in vitro fertilization.
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Projected lifetime net revenues from the IVF cohort are 
illustrated in Figure 1, where changes in NPV depending 
on the age of the IVF cohort are observed. While in the 
early stages of an individual’s life, net monetary flows are 
negative for the government since education, health and 
social support are provided to the family by state without 
financial returns, during the working years, the individual’s 
financial balance tips positive for the government, as state 
revenue is collected as tax payments and lower social 
expenses are paid. Advancing in age, individuals begin 
to provide less revenue to the state while simultaneously 
receiving increased social spending, primarily because of 
pension payments. Because the net revenue positions for 
an IVF-conceived and a naturally-conceived child follow 
similar trajectories, where the only difference between 
the two is the additional cost of IVF investment required 
for conception, Figure 1 presents the NPV for an IVF-
conceived individual only. In light of the observed differ-
ence in expenses on population in the three study countries, 
IVF may be considered an attractive economic option in 
Ukraine, Belarus, and Kazakhstan, with discounted NPVs 
of $9,839, $21,702, and $2,295, respectively (Table 2). 
When country-specific IVF birth rates were applied in the 
model considering both IVF success rate and multiple preg-
nancies (Table 2), the results did not change significantly. 
A possible explanation for the small impact of higher-cost 
IVF children stems from the positive economic impact 
of the individual in general. As such, higher frequency 
of multiple births in IVF population compensates for the 
additional expenses related to IVF newborns and the higher 
mortality during neonatal stage.
The PSA based on 5,000 simulations shows that the 
average NPV per person remains positive: $1,894±$7,619, 
$27,925±$12,407, and $17,229±$24,637 in Ukraine, 
Belarus, and Kazakhstan, respectively. At the same 
time, the ranges and standard deviations for Ukraine 
and  Kazakhstan indicate that under some circumstances 
 (meaning of inputs), financing of IVF can become negative 
for these countries.
The results of one-way sensitivity analysis (Table 3) show 
a positive NPV until the mother’s age is over 42 years in 
Ukraine and Belarus, while in Kazakhstan the break-even age 
of the mother (age at which financing IVF remains economi-
cally beneficial for the government) is 38–40 years. The costs 
of IVF drugs and supplies impact significantly the results 
of the economic analysis. A negative NPV was obtained 
using a discount rate of 10% in all three countries, as well 
as with a discount rate of 0% in Belarus and Kazakhstan. In 
the PSA, with a fixed 0% discount rate, a negative NPV was 
obtained for Ukraine and Kazakhstan ($19,962±$33,263 
and $44,084±$89,815, respectively) and positive for Belarus 
($24,328±$63,580). The instability of these results is indi-
cated by the value of the standard deviation, which exceeds 
the average value.
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Figure 1 Projected net present value for child conceived by iVF in Ukraine, Belarus, and Kazakhstan.
Abbreviations: iVF, in vitro fertilization; nPV, net present value.
ClinicoEconomics and Outcomes Research 2015:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
352
Mandrik et al
to life-saving technologies is especially important in 
jurisdictions where financial resources are limited, such as 
in low-income and middle-income countries like Ukraine, 
Belarus, and Kazakhstan. Economic evidence in terms of cost 
minimization or budget impact techniques may be applied 
to rationalize financing a limited number of IVF cycles, 
or to define an intent-to-treat patient population. While in 
Belarus nearly 600 children were born via state-financed IVF 
treatments,23 Ukraine,16 and Kazakhstan together report about 
600 IVF cycles to be state-financed annually (personal com-
munication), although in Kazakhstan this number is expected 
to rise in 2015. The present research shows that financing IVF 
may have a positive NPV, not only in high-income but also in 
lower-income countries. Based on the average cost per child 
conceived with IVF in a state clinic and using current levels 
of financial flows between populations and governments of 
Ukraine, Belarus, and Kazakhstan, the discounted returns 
to state all were positive over the projected lifetime of an 
individual, with higher uncertainty of results for Ukraine and 
Kazakhstan. A higher NPV from financing IVF in Ukraine, 
Belarus, and Kazakhstan can be achieved by limiting cov-
erage of the procedure to women of younger age and by 
negotiating lower prices with IVF drug suppliers.
In Western European countries and Brazil, the discounted 
NPV of IVF ranged from $61,428 (Brazil) to $177,002 (UK; 
exchange rate 1 pound = US$ 1.61 on September 9, 2014), 
while in the countries of the Central and Eastern European 
region studied here the financial returns to the state were 
significantly lower, although still positive.3–8 However, 
an interesting observation from this study is that the NPV 
derived from an IVF population may not always be propor-
tional to the income level of the country, expressed in GDP 
per capita. For example, the lowest financial return in the 
present study was observed in the country with the highest 
GDP per capita, ie, Kazakhstan. It should be noted that GDP 
per capita is not always the best approach for evaluating the 
income of a country’s population, as wealth can be distributed 
unequally, an especially common case in countries with a 
developing economy. Meanwhile, it also may be assumed that 
state income from population may not be related linearly to 
the country’s wealth in general in cross-country comparisons, 
because of differences in taxation policies and government 
spending.
Another interesting conclusion resulted from the proba-
bilistic model applied, in which we tried to account for pos-
sible changes of the input parameters that may be expected 
during the long run of the model (lifetime of the IVF cohort). 
While applying the individual prognostic factors for each 
Table 3 One-way sensitivity analysis (mothers’ age, iVF drug 
costs, and discounting rate)
Scenario Lifetime NPV (US$)
Ukraine Belarus Kazakhstan
nPV of child conceived by iVF,  
mother aged ,35 years  
(40.1% success rate)
10,339 22,770 3,061
nPV of child conceived by iVF,  
mother aged 38–40 years  
(21.6% success rate)
8,673 19,212 507
nPV of child conceived by iVF,  
mother aged 41–42 years  
(12.2% success rate)
5,890 13,270 negative
nPV of child conceived by iVF,  
mother aged .42 years  
(4.2% success rate)
negative negative negative
Cost of iVF drugs, 50% increase 8,691 19,183 650
Cost of iVF drugs, 100% increase 7,544 16,663 negative
Break-even cost of iVF drugs  
and supplies per cycle, $
3,870 8,530 1,780
Cost of pregnancy and delivery,  
50% increase
9,782 21,583 2,150
Discounting rate, 0% 10,986 negative negative
Discounting rate, 5% 1,544 13,907 1,826
Discounting rate, 10% negative negative negative
Abbreviations: iVF, in vitro fertilization; nPV, net present value.
Table 2 Cost and income of iVF-conceived population in Ukraine, 
Belarus, and Kazakhstan
Scenario Lifetime NPV* ($)
Ukraine Belarus Kazakhstan
Expenses
  social (maternity) support  
and sick leaves
2,976 5,734 5,700
  Education 4,045 6,021 7,050
  health care costs 7,617 35,463 42,024
  Unemployment 31 2.17 52,342
  Pension 8,881 55,852 45,125
  Total state expenses  
on iVF population
26,150 106,580 104,108
Revenue
  Revenue from population 37,687 128,282 106,403
net income
  net present value of iVF 9,839 21,702 2,295
  net present value of iVF in  
country-specific scenarios
8,879 21,139 2,040
Note: *average per birth.
Abbreviations: iVF, in vitro fertilization; nPV, net present value.
Discussion
The results presented in this paper show how public financ-
ing of IVF in three former Soviet Union countries (Belarus, 
Kazakhstan, and Ukraine) will generate a positive return 
to the state in future tax contributions. Understanding the 
 financial benefits from medical technologies not related 
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country, it appeared that the NPV in the probabilistic model 
may differ from the deterministic model, a finding explained 
by differences in economic forecast for a long time horizon. 
Moreover, opposite the deterministic model, the NPV of the 
IVF population may be higher in Kazakhstan than in Ukraine, 
if changes in the taxation policy (which are currently under 
political discussion) are applied in the future. Because of the 
long horizon of generational accounting models, we sug-
gest that it is obligatory to apply PSA in order to define the 
stability of the received results under conditions of possible 
political and economic change.
The sensitivity analysis with the 0% discount rate has 
shown the inaccuracy of using this value in a life-duration 
model based on generational accounting. The assumption 
in the model that annual expenses increase proportionally 
to GDP makes the expenses on the retired population inac-
curately higher than on the working population in countries 
with larger values for pensions and GDP growth.
The generational accounting framework from the gov-
ernmental perspective used in this model assesses costs and 
benefits attributed to conceiving an IVF child as an invest-
ment required to achieve a live birth with consequent long-
term economic returns. This economic model was used to 
assess the cost efficiency of state investments in countries 
with nationally funded health services (Ukraine, Belarus, 
and Kazakhstan) where both investments (financing IVF 
procedures) and returns (tax received) will present a financial 
flow between two stakeholders, population, and state. This 
model may be potentially applied to other countries with 
similar political, economic, and health care structures, where 
major state revenues are expected to come from tax payments 
(such as Russia, Georgia, or Azerbaijan). While the results 
of the current study show a positive economic balance with 
stability of the received results by PSA in Ukraine, Belarus, 
and Kazakhstan, the transferability of the model to other 
countries of the region may be assessed in the future.
In most Western European countries, a complete IVF 
treatment consists of a maximum of three IVF cycles, 
where treatment choices for each cycle can differ. In a cost-
effectiveness analysis reflecting the “real-world” situation 
conducted in the Netherlands, it was found that combining 
several transfer policies was not cost-effective, and so the 
single-choice treatment option should be preferred, ie, elec-
tive single embryo transfer, standard treatment policy, or 
double embryo transfer.24
A cost-effectiveness analysis of replacing one, two, or 
three embryos per cycle of IVF in specific populations of 
women (,38 years, $38 years; one cycle, two cycles, and 
three or more cycles) has shown that the most cost-effective 
and least cost-effective scenarios occurred, respectively, 
with younger and older women who received three or more 
cycles, in the move from one embryo transfer to two embryo 
 transfers.25 Meanwhile, in the current study, we assessed only 
two scenarios: expenses and incomes related to one birth only, 
with the IVF success rate aiming at the minimum budget 
impact for the intervention financing; expenses and incomes 
related to IVF birth according to the current countries’ data 
on multiple births and cycle success rate. Taking into con-
sideration cost-efficiency of the different IVF procedures 
in future studies may show increases in state benefits from 
IVF financing.
limitations
While taxation-based income may represent a reasonably 
accurate means of estimating future economic benefits for 
the state, it should be noted that population also contributes 
to other financial governmental flows, such as trade and 
enterprise development, which was not accounted for in the 
current model. The model also did not account for possible 
emigration of people to other countries. This may particularly 
affect the results of economic studies in Belarus, where the 
unemployment rate is assessed by the number of people 
receiving unemployment support from the government.
The model accounts for linear increases in spending 
and earning, based on average values from a retrospective 
historical assessment of the countries’ input parameters. 
As a consequence, the impact of unpredictable economic 
crises or growth also was not accounted for in the evalua-
tion. Another model limitation is that the calculation applied 
average earnings in the population, ignoring the possibility 
of wealthier generations in the future. While the return of 
state investments was assessed from the narrow governmen-
tal perspective using only future net tax contributions, we 
may consider that with broader assessment of net marginal 
contributions from individuals, the net state benefit from 
IVF-conceived children will present an even more attractive 
economic option.
Conclusion
The results of this study may have implications for IVF 
 reimbursement policy not only in Ukraine, Belarus, and 
Kazakhstan, but in other settings with comparable popula-
tions and financial flows between population and govern-
ments, particularly those which may be considering universal 
coverage for fertility treatments. While income from a popu-
lation may not be directly proportional to GDP per capita, 
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it appears that financing IVF technologies collectively may 
represent a promising potential for state financial returns.
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Table S1 input parameters in deterministic and probabilistic models
Parameter Country Deterministic  
data
Minimum  
meaning
Maximum  
meaning
Reference
gDP, $ Ukraine 3,615 2,985.5 7,600 1–3
Belarus 6,480 5,820 16,000 1,3,4
Kazakhstan 11,356 11,356 13,900 1,3
gDP growth, % Ukraine 4.03 0.20 5.20 5,6
Belarus 7.74 4.30 7.74 5,6
Kazakhstan 7.46 1.2 8.9 5
Total tax rates as %  
from salaries
Ukraine 55.36 33.60 55.36 7
Belarus 47.54 42.79 52.29 8
Kazakhstan 31.00 31.00 37.20 9
average monthly  
salary for males, $
Ukraine 379.37a 289.75 637.91 2
Belarus 483.94a 421.49 620.14 10,11
Kazakhstan 779.00b 598.85 1,564.53 12–14
average monthly  
salary for females, $
Ukraine 301.73a 230.45 507.35 2
Belarus 384.90a 335.22 439.22 10–12
Kazakhstan 410.85b 315.77 824.98 13–15
average monthly  
pension, $
Ukraine 129.24 104.84 145.72 2,16,17
Belarus 219.94 99.32 228.44 11,12
Kazakhstan 240.24 192.19 269.07 18
average monthly  
unemployment  
support, $
Ukraine 82.02c 68.06 103.22 2,16,17
Belarus 17.00c 13.33 20.00 19
Kazakhstan 119.72d 95.78 143.66 20
Unemployed from  
working population, %
Ukraine 7.00 6.40 8.80 2,21
Belarus 1.00 0.50 1.60 19,22
Kazakhstan 5.20 5.20 6.60 14,23,24
Retired population  
working, %
Ukraine 15.00 13.50 18.00 2
Belarus 22.00 19.80 26.40 12
Kazakhstan 16.00 14.40 19.20 14
Retirement age males,  
years
Ukraine 60e 60 65 16,25
Belarus 6e 60 65 16,25
Kazakhstan 63e 63 65 25,26
Retirement age  
females, years
Ukraine 60e 60 65 16,25
Belarus 55e 55 65 16,25
Kazakhstan 58e 58 65 25,26
state expenditure  
on education, $
Ukraine 247.94 191.60 253.05 2,27
Belarus 291.60 336.96 453.60 22,28
Kazakhstan 352.65 340.68 681.36 24,28
state expenditure  
on health care, $
Ukraine 231.49 231.49 253.05 29
Belarus 362.88 362.88 453.80 29
Kazakhstan 488.31 488.31 794.92 29
Fertility success rate, % 31.9 31.20 32.5 30
Discounting, % 3.00 – – 31
Notes: aassumption 22.8% difference in male/female salaries according to state statistics report (Ukraine);2 bassumption 61.9% difference in male/female salaries according 
to state statistics report (Kazakhstan);14 caverage monthly support received for 12 months; daverage monthly support received for maximum 4 months (under the law “On 
obligatory social insurance” of the Republic of Kazakhstan); eassumed that retirement age will not be lowered from existing.
Abbreviation: gDP, gross domestic product.
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